SB299 Alabama 2025 Session

Summary

Primary Sponsor

Tim Melson Senator

Republican

Session

2025 Regular Session

Title

Stem cell therapy; permitted in certain circumstances, notice and consent requirements provided, exceptions provided, State Board of Medical Examiners required to adopt rules

Description

This bill would permit a health care provider whose scope of practice includes stem cell therapy to perform stem cell therapy that is not approved by the United States Food and Drug Administration (FDA), provided the health care provider gives the patient written notice about the nature, anticipated results, and recognized risks of the stem cell therapy and obtains written consent before performing the therapy.

This bill would require health care providers who offer stem cell therapy in accordance with this bill to post a notice in the health care provider's office and accompanying any advertisement for the therapy stating that the therapy has not been approved by the FDA.

This bill would define the term "stem cell therapy" to include the use of afterbirth placental perinatal stem cells or human cells, tissues, or cellular or tissue-based products, but not any treatment or research using human cells or tissues that were derived from a fetus or embryo after an abortion.

This bill would provide exemptions for certain therapies which are approved for investigational use by the FDA or performed under an employment or other contract with certain entities.

SB299 INTRODUCED This bill would provide that a violation is unprofessional conduct for purposes of licensure with the State Board of Medical Examiners.

This bill would also require the State Board of Medical Examiners to adopt rules.

Show more Show less

Subjects

Health